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ABSTRACT
The incretin hormones, glucose-dependent insulinotropic peptide and glucagon-like pep-
tide-1, are secreted from intestinal K- and L cells, respectively, with the former being most
abundant in the proximal small intestine, whereas the latter increase in number towards
the distal gut. Although an overlap between K- and L cells can be observed immunohis-
tochemically or in murine models expressing fluorescent markers under the control of the
two hormone promoters, the majority (>80%) of labeled cells seems to produce only one
of these hormones. Transcriptomic analysis showed a close relationship between small
intestinal K- and L cells, and glucose sensing mechanisms appear similar in both cell types
with a predominant role of electrogenic glucose uptake through sodium-coupled glucose
transporter 1. Similarly, both cell types produce the long-chain fatty acid sensing G-pro-
tein-coupled receptors, FFAR1 (GPR40) and FFAR4 (GPR120), but differ in the expression/
functionality of other lipid sensing receptors. GPR119 and FFAR2/3, for example, have
clearly documented roles in glucagon-like peptide-1 secretion, whereas agonists for the
endocannabinoid receptor type 1 have been found to show largely selective inhibition of
glucose-dependent insulinotropic peptide secretion. In conclusion, although K- and L cell
populations overlap and share key molecular nutrient-sensing mechanisms, subtle differ-
ences between the responsiveness of the different cell types might be exploited to differ-
entially modulate glucose-dependent insulinotropic peptide or glucagon-like peptide-1
secretion.
INTRODUCTION
Glucose-dependent insulinotropic polypeptide (GIP) and gluca-
gon-like peptide-1 (GLP-1) are gut hormones secreted from
specialized enteroendocrine cells within the intestinal epithe-
lium. They are released postprandially and act as circulating
markers of food consumption, enabling the body to respond
appropriately to food-derived elevations of blood nutrient con-
centrations. This is crucial for the control of blood glucose con-
centrations, as costimulation of pancreatic b-cells by GIP and
GLP-1 approximately doubles the amount of insulin released in
response to an elevation in ambient (blood) glucose concentra-
tions. GLP-1 and GIP are hence often termed ‘incretins,’ and
underlie the ‘incretin effect’ – a well-documented observation
that intravenous glucose infusion at a rate that simulates
postprandial blood glucose levels triggers only about half as
much insulin release as a matched oral glucose challenge. After
the discovery that the insulinotropic effect of GLP-1 is pre-
served in most people with type 2 diabetes1, GLP-1 mimetics
and inhibitors of GLP-1 degradation by dipeptidyl peptidase 4
have been developed and licensed for the treatment of type 2
diabetes2.
Although a wealth of evidence supports the idea that both
GLP-1 and GIP underlie the incretin effect, there are important
differences in the activity and plasma proﬁles of the two hor-
mones. GIP, for example, stimulates glucagon secretion from
pancreatic a-cells, whereas GLP-1 inhibits a-cell activity. GLP-
1, in contrast, has anorexigenic properties, whereas GIP seems
to have no effects on food intake. GIP is instead considered
pro-adipogenic, based on several observations, including that
knockout of the GIP-receptor3 or immunoneutralization of
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circulating GIP4 are protective against diet-induced obesity in
rodents. As the incretin action of GIP seems to be impaired in
patients with type 2 diabetes1, it might be postulated that a
stimulation of GLP-1 and an inhibition of GIP secretion could
be a therapeutic objective in overweight patients with type 2
diabetes. Further understanding the differences between these
two hormones should enable a more targeted approach to their
exploitation for the treatment of diabetes and obesity. The pre-
sent review will focus on the physiology of the enteroendocrine
cells secreting these two hormones, the GIP-expressing K cells
and the proglucagon/GLP-1-expressing L cells.
LOCATION: OVERLAPPING BUT DISTINCTIVE
POPULATIONS OF K- AND L CELLS
GIP-containing cells are found at highest density in the duode-
num in a number of species5–7. GLP-1-containing cells can also
be found in the proximal small intestine, but increase in num-
ber towards the distal small intestine, and in contrast to K cells
are also numerous in the colon and rectum (Figure 1). Based
on immunohistochemical staining, so-called LK cells have been
described, which were immune-positive for both GIP and GLP-
18,9. In transgenic mice expressing ﬂuorescent markers under
the control of either the GIP or the proglucagon promoter, cells
producing the ‘other’ incretin have also been observed; that is,
GIP in cells labeled by the proglucagon promoter, and GLP-1
in cells labeled by the GIP promoter10; however, these double-
positive cells only amounted to ~10–20% of the total K- and
L cell population. Overall secretory responses from cell popula-
tions in vivo or in vitro are thus likely to be dominated by the
remaining ~80% of single-positive cells that produced only
GLP-1 or GIP6, and as we describe below, selective stimulation
or inhibition of either GIP or GLP-1 secretion is therefore pos-
sible. Nevertheless, the observation that K- and L cells addition-
ally produce other hormones, such as CCK10, challenges the
traditional classiﬁcation of enteroendocrine cells according to
their expression of one (or sometimes two) speciﬁc hormones,
and suggests a more plastic expression proﬁle that could be
affected by external factors, such as the recent exposure of the
intestine to nutrients and other luminal stimulants. Given the
relatively rapid turnover of enteroendocrine cells in the small
intestine every ~5 days11, it seems plausible that recent nutri-
tional availability could result in changes to the overall
enteroendocrine cell population within days or weeks. In a
recent study to identify the effects of a high-fat diet on mouse
L cells, however, we observed a general downregulation of
many enteroendocrine cell-speciﬁc genes rather than a switch
to the preferential production of an alternative hormone12.
GLUCOSE SENSING: SIMILAR MECHANISMS OPERATE
IN BOTH K- AND L CELLS
Given the importance of both GIP and GLP-1 for the incretin
effect, one of the most investigated secretory stimuli of gut hor-
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Figure 1 | L- and K cell distribution and stimulus detection machinery. The majority of K cells are more proximally located than L cells. Fasting and
postprandial glucose-dependent insulinotropic polypeptide (K cells) and glucagon-like peptide-1 (L cells) secretion likely reflect the dynamic
gradient of different intestinal stimuli along the gut. Physiological activation of the L- and K cell detection pathways is shown, involving
transporters/ion channels (linked to altered cellular electrical activity) and G-protein-coupled receptors, differing between the small intestine and
colon. ATA2, amino acid transporter A2 (solute carrier [Slc] Slc38A2); BOAT1, system B(0) neutral amino acid transporter AT1 (Slc6A19); CASR,
calcium-sensing receptor; CB1, cannabinoid receptor 1; EEC, enteroendocrine cell; FFAR, free fatty-acid receptor; GPBAR1, G-protein coupled bile-acid
receptor 1; GPR119, G-protein coupled receptor 119; GPRC6A, G-protein coupled receptor classC 6A; Kv-channels, voltage gated potassium
channels; SGLT1, sodium-coupled glucose transporter 1 (Slc5A1); Tas1R, taste receptor type 1.
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mone secretion is glucose. Both K- and L cells in mixed
primary intestinal epithelial cultures failed to respond to glucose
when the sodium-coupled glucose transporter 1 (SGLT1) was
inhibited either pharmacologically or genetically13–16. Indeed, a
wealth of in vitro and in vivo data have suggested that the
rapid elevations in plasma GIP and GLP-1 concentrations after
glucose ingestion are directly linked to the electrogenic uptake
of glucose by K- and L cells, resulting in membrane depolariza-
tion, voltage-gated calcium entry and enhanced rates of vesicu-
lar exocytosis17. More extensive phenotyping of global SGLT1
knockout mice, however, showed differences between the
release patterns of GIP and GLP-1, which are likely related to
the different locations of K- and L cells along the gastrointesti-
nal tract axis18. In this mouse model, the GIP response to an
oral glucose tolerance test was abolished, consistent with the
proposed SGLT1-dependent coupling of glucose absorption to
GIP secretion in K cells. By contrast, whereas the early GLP-1
response ~5 min after a glucose gavage was abrogated in
SLGT1 knockout mice or in mice treated with an SGLT1 inhi-
bitor13,18, elevated plasma GLP-1 concentrations were observed
at later time-points18. The ﬁndings support the idea that the
rapid secretion of GLP-1 and GIP from the proximal small
intestine after a glucose load is linked to SGLT1-dependent glu-
cose absorption, but suggest that alternative sensory mecha-
nisms operate in the distal gut. Inhibition of glucose absorption
in the upper gastrointestinal tract in SGLT1 knockout mice
results in a dramatic increase in glucose delivery to the distal
gut with its higher density of L cells18, likely underpinning the
delayed elevation of GLP-1 levels in these mice. The mecha-
nism by which this glucose load is sensed by the distal ileum
and/or colon remains unclear. Candidate pathways include the
bacterial fermentation of distally-delivered carbohydrate to
metabolites, such as short chain fatty acids that are then sensed
by G-protein-coupled receptors, such as GPR4319, or metabo-
lism of the sugar within L cells resulting in the activation of an
alternative downstream signaling pathway. Neither of these
hypotheses has yet been validated experimentally.
Whereas the SGLT1-dependent pathway is common to K-
and L cells, we observed some differences between the respon-
siveness of the glucose-sensing machinery underlying GIP and
GLP-1 secretion from small intestinal primary murine epithelial
cultures. Whereas a-methyl-glucopyranoside, a non-metaboliz-
able SGLT1 substrate, enhanced GLP-1 secretion in the absence
of other stimuli16, it only became an effective GIP secretagogue
at elevated cyclic adenosine monophosphate (cAMP) levels14.
Interestingly, the responsiveness to tolbutamide, an inhibitor of
adenosine triphosphate-sensitive potassium (KATP) channels,
showed the reverse dependence, triggering GIP responses in the
absence, but not presence, of the cAMP-raising agents, forskolin
and 3-isobutyl-1-methylxanthine (IBMX)14. KATP channel clo-
sure has itself been postulated as a mechanism underlying K-
and L cell glucose sensing, similar to its well-established role in
mediating glucose-dependent insulin secretion from pancreatic
b-cells. In support of this idea, KATP channel inhibition
enhanced GIP and GLP-1 secretion from intestinal cultures,
triggered GLP-1 secretion from the enteroendocrine cell line,
GLUTag20, and increased GLP-1 release from perfused rat
intestine21. However, there is little data supporting the idea that
KATP channel closure triggers gut hormone secretion in an
intact animal. Mice lacking the KATP channel subunit Kir6.2
did not show impaired glucose-triggered gut hormone secre-
tion22,23; and in humans, the KATP channel inhibitor, gliben-
clamide, had no effects on GIP and GLP-1 concentrations
before or during an oral glucose tolerance test24. KATP-channel
closure has, however, been suggested to underlie fructose-stimu-
lated GLP-1 secretion25. Fructose is not a substrate for sodium-
coupled monosaccharide transport, and instead enters cells
through the facilitative transporter GLUT5. Interestingly, fruc-
tose does not stimulate GIP secretion in healthy rodents and
humans25, but GIP release in response to fructose has been
reported in diabetic mouse models22,26. However, opening of
KATP-channels with diazoxide did not abolish fructose-stimu-
lated GIP secretion in diabetic mice, and even the GLP-1
response to oral fructose remained intact in mice lacking the
KATP channel subunit, Kir6.2
23. In view of the widespread
agreement that KATP channels are expressed and functional in
K- and L cells, the results unanimously support the idea that
the resting KATP conductance is already very small in native K-
and L cells in vivo, and that any differences observed between
in vivo and in vitro experiments might reﬂect differences in the
metabolic status of the enteroendocrine cells under the different
conditions.
Another physiological glucose-sensing mechanism involves
the G-protein-coupled receptor heterodimer of TAS1R2 and
TAS1R3, that underlies sweet taste sensation in the tongue.
Impaired postprandial GLP-1 levels have been observed in mice
lacking a-gustducin, a component of the downstream taste
receptor signaling pathway27, and both GIP and GLP-1 secre-
tion have been reported from the GLUTag cell line in response
to high concentrations of artiﬁcial sweeteners28. We, however,
were unable to show a role for TAS1R2/3 in hormone secretion
from murine K- or L cells in primary culture14,16, and artiﬁcial
sweeteners failed to elevate plasma incretin hormone levels in
human volunteers29. Other studies also failed to show artiﬁcial
sweetener-stimulated GIP secretion in mice in vivo22 or GLP-1
secretion in a perfused rat intestinal preparation21, questioning
the importance of TASR1R2/3 in incretin secreting cells.
G-PROTEIN-COUPLED RECEPTORS: CANDIDATES FOR
SELECTIVELY TARGETING K- AND L CELLS
The development of transgenic mice with ﬂuorescently tagged
K- or L cells has enabled the transcriptomic analysis of these
different cell types. Similarities and differences between K- and
L cell populations were observed for the expression of a num-
ber of G-protein-coupled receptors. Both K- and L cell popula-
tions, for example, were found to express messenger ribonucleic
acids (mRNAs) encoding the free-fatty acid receptors, FFAR1
(GPR40) and FFAR4 (GPR120)14,16. GPR40 activation has, for
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example, been linked to the stimulation of GLP-1 secretion in
experiments using Gpr40 knockout mice30, as well as by the
application of GPR40 agonists to the perfused rat intestine31.
Recent data, by contrast, convincingly showed a reduction in
lard-triggered GIP-responses in mice lacking Gpr12032. In pri-
mary intestinal cultures from mice lacking either Gpr40 or
Gpr120, however, we observed diminished secretion of both
GIP and GLP-1 in response to oleate (Reimann and Gribble
unpublished observation). Thus, although the data linking
GPR120 activation to GIP secretion and GPR40 activation to
GLP-1 release are robust, it is currently unclear whether either
of these receptors plays a relatively greater role in any particular
enteroendocrine cell type.
Other lipid-derived stimulants, such as mono-acyl-glycerol,
activate GPR119, mRNA for which is expressed in both K- and
L cells14,16. Whereas a small molecule GPR119 agonist elevated
GLP-1 and GIP concentrations in mice33, however, the natural
GPR119 ligand oleoylethanolamide (OEA) was not a good
stimulus of GIP-secretion from primary epithelial cultures14.
GLP-1 secretion, by contrast, was stimulated by OEA from
both small and large intestinal-derived murine cultures34. In the
colon, this was mediated by GPR119, as shown by the loss of
OEA-triggered GLP-1 release in colonic cultures from mice
lacking GPR119 speciﬁcally in proglucagon expressing cells.
Similar experiments carried out in small intestinal cultures from
these mice, however, showed that the OEA-triggered GLP-1
secretory response in the upper gastrointestinal tract was not
GPR119-dependent34, suggesting that OEA recruits alternative
mechanisms in duodenal/jejunal L cells, and that this pathway
might not be sufﬁciently active in K cells to trigger GIP secre-
tion.
The related compounds, mono-arachidonoyl-glycerol and
arachidonoylethanolamine (anandamide), are agonists for the
endocannabinoid receptor, CB1 (encoded by the gene Cnr1),
which is predominantly Gi-coupled. Cnr1 is highly expressed in
small intestinal K- and L cells, with a tendency for higher
expression in K- than L cells, but was not detected in L cells
from the colon35. Consistent with the known Gi coupling of
CB1, anandamide was shown to inhibit IBMX-triggered GIP
secretion in vivo, an effect that was blocked by the CB1-antago-
nist AM251. Interestingly, GLP-1 secretion from the same cul-
tures was not affected by anandamide, despite the relatively
high expression of Cnr1 in small intestinal L cells. Pretreatment
of mice with anandamide delayed GIP, but not GLP-1
responses to an oral glucose tolerance test35. These ﬁndings
raise questions about why the same receptor is apparently more
effectively coupled to inhibition of secretion in K- than L cells,
despite relatively high expression levels in both.
Ligands for other predominantly Gi-coupled receptors
expressed in both K- and L cells, by contrast, tend to have simi-
lar effects on both GIP and GLP-1 secretion. Somatostatin
strongly suppressed the elevation of cAMP triggered by forskolin
and/or IBMX in both cell types, and the effect was at least partly
mediated through SSTR535. The most likely sources of somato-
statin are nearby intestinal D cells, this being an example of
how paracrine signals can integrate responses to luminal signals
within the epithelium. Galanin, most likely secreted from enteric
neurons, similarly recruits GALR1 in both K- and L cells, result-
ing in a Gi-dependent suppression of cAMP levels
36, and exem-
plifying that enteroendocrine cells likely integrate responses to
luminal nutrients with signals arriving through the enteric ner-
vous system. Gi-coupled receptors, such as GALR1, have been
reported to inhibit electrically excitable cells through activation
of G-protein activated inwardly rectifying potassium (GIRK)
channels, mediated by the G-protein bc-subunit. Interestingly,
whereas both K- and L cells showed enriched expression of
mRNAs encoding GIRK channels, and although GIRK-inhibi-
tion had no effect on the ability of galanin to inhibit GLP-1
secretion, only GLP-1, but not GIP, secretion could be inhibited
by co-application of the GIRK-activator, ML297, with IBMX or
glucose36. This might point to a difference in the role of potas-
sium conductances in the stimulus secretion coupling of K- and
L cells, but further work assessing possible differences in the
electrical activity of these enteroendocrine cell types and its
relationship to hormone secretion is required.
Given the calcium dependence of a number of proteins
involved in the exocytotic pathway, predominantly Gq-coupled
receptors should be good targets to stimulate incretin secretion.
The similar expression levels in K- and L cells of mRNAs
encoding the Gq-coupled receptor, FFAR1, have been men-
tioned above. The related short-chain fatty acid receptor FFAR2
(GPR43) by contrast seems more abundant in L- than K cells
(Affymetrix chip array probe 1425216 RMA-values are 2,143
for ﬂuorescently tagged L- and 154 for ﬂuorescently tagged
K cells isolated from the small intestine, with the latter value
being similar to values observed for the non-ﬂuorescent control
cells; Reimann and Gribble unpubl.), supporting the reported
importance of GPR43 in short-chain fatty acid stimulated GLP-
1 secretion19. However, whereas ﬂuorescent reporter mice for
FFAR2 had only a few labeled enteroendocrine cells, reporter
mice for the other short chain fatty acid receptor FFAR3
(GPR41) showed strong labeling of a number of enteroen-
docrine cells in the small intestine, including K- and L cells37.
A recent publication reported a blunting of GLP-1, but not
GIP, secretion in response to orally-administered butyrate in
Ffar3 knockout mice38, and further work will be required to
clarify the relative roles of these receptors in incretin-secreting
cells. Another Gq-coupled receptor, presumably underlying
modulation of enteroendocrine secretion by the enteric nervous
system, as it is activated by neuromedin C and gastrin-releasing
peptide, is the bombesin receptor 2. Bombesin receptor 2
mRNA was found to be selectively enriched in L cells, but not
K cells, and, consistent with this ﬁnding, bombesin increased
calcium concentrations in L cells, but not K cells, and triggered
GLP-1, but not GIP, secretion from primary small epithelial
cultures as well as in a perfused intestinal preparation39.
Whether any of the predominantly Gq-coupled receptors will
be good targets for selective stimulation of GLP-1 secretion
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in vivo will have to await further research. It should be noted,
however, that a recent report of a so-called FFAR1 ‘superago-
nist,’ capable of triggering robust GLP-1 secretory responses,
stresses the importance of the dual action of such compounds
in recruiting both Gq- and Gs-coupled pathways
40. This latter
notion is supported by our observation that raising intracellular
cAMP levels with forskolin and IBMX boosts GIP and GLP-1
secretory responses to a number of agents that elevate
enteroendocrine cell cytosolic Ca2+ concentrations, in primary
epithelial cultures17. A predominantly Gs-coupled receptor
expressed in L cells, but not K cells, is the melanocortin recep-
tor 4, and increased GLP-1 and PYY secretion in response to
agonists has been shown41, although currently the nature or
source of the physiological ligand for this receptor on L cells is
uncertain. Other predominantly Gs-coupled receptors, expres-
sion of which is enriched in L cells, include GPR119 (see
above) and the bile acid-sensitive receptor, GPBAR1 (TGR5).
Although there seems to be some expression of Gpbar1 in
K cells, it is not enriched compared with the surrounding cells
(Reimann and Gribble unpublished observation), making
GPBAR1 one of the more promising receptors to ‘selectively’
stimulate GLP-1 secretion. However, we recently showed that
bile acids need to access the basolateral rather than the apical/
luminal surface of L cells to stimulate GLP-1 secretion through
GPBAR142, and a similar observation was reported for agonists
of GPR4031. As melanocortin receptor 4 was also located to
the basolateral side41, the interesting question arises if any
GPCRs directly sample the luminal contents. If all L cell
GPCRs are instead located on the basolateral membrane, the
potential hope to develop agents with limited systemic bioavail-
ability to avoid off-target side-effects as a result of action on
other cells expressing the receptors in question would be
unfounded.
CONCLUSION
Although the success of GLP-1 analogs/mimetics in the treat-
ment of type 2 diabetes and the correlation of strongly elevated
postprandial GLP-1 levels after Roux-Y gastric bypass surgery43
strongly suggests beneﬁts of recruiting endogenous GLP-1
reserves as a not yet exploited treatment alternative, the situa-
tion for GIP is less clear. Arguments have been put forward for
developing both GIP-receptor agonists and antagonists44. The
differences observed in murine K- and L cells suggest that it is
possible to elevate one incretin preferentially by external stimuli,
but further work will be required before translation into a clini-
cal therapy.
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